1740 related articles for article (PubMed ID: 11303370)
21. The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication.
Wheeldon TU; Granström M; Hoang TT; Phuncarg DC; Nilsson LE; Sörberg M
Aliment Pharmacol Ther; 2004 Jun; 19(12):1315-21. PubMed ID: 15191514
[TBL] [Abstract][Full Text] [Related]
22. Long-term follow-up after eradication of Helicobacter pylori with omeprazole, clarithromycin, and tinidazole (OCT regimen) in a Japanese population.
Ando T; Minami M; Mizuno T; Watanabe O; Ishiguro K; Ina K; Kusugami K; Nobata K; Nishiwaki T; Tsuzuki T; Shimada M; El-Omar E; Goto H
Helicobacter; 2005 Oct; 10(5):379-84. PubMed ID: 16181347
[TBL] [Abstract][Full Text] [Related]
23. Do some patients with Helicobacter pylori infection benefit from an extension to 2 weeks of a proton pump inhibitor-based triple eradication therapy?
Maconi G; Parente F; Russo A; Vago L; Imbesi V; Bianchi Porro G
Am J Gastroenterol; 2001 Feb; 96(2):359-66. PubMed ID: 11232676
[TBL] [Abstract][Full Text] [Related]
24. Comparison of 1-week and 2-week triple therapy with omeprazole, amoxicillin, and clarithromycin in peptic ulcer patients with Helicobacter pylori infection: results of a randomized controlled trial.
Kiyota K; Habu Y; Sugano Y; Inokuchi H; Mizuno S; Kimoto K; Kawai K
J Gastroenterol; 1999; 34 Suppl 11():76-9. PubMed ID: 10616771
[TBL] [Abstract][Full Text] [Related]
25. Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection.
Murakami K; Okimoto T; Kodama M; Sato R; Miyajima H; Ono M; Inoue K; Watanabe K; Otsu S; Fujioka T
Helicobacter; 2006 Oct; 11(5):436-40. PubMed ID: 16961805
[TBL] [Abstract][Full Text] [Related]
26. Cure of Helicobacter pylori infection: role of duration of treatment with omeprazole and amoxicillin.
Adamek RJ; Opferkuch W; Pfaffenbach B; Wegener M
Am J Gastroenterol; 1996 Jan; 91(1):98-100. PubMed ID: 8561153
[TBL] [Abstract][Full Text] [Related]
27. Omeprazole-based antimicrobial therapies: results in 198 Helicobacter pylori-positive patients.
Deltenre M; Jonas C; van Gossum M; Buset M; Otero J; De Koster E
Eur J Gastroenterol Hepatol; 1995 Aug; 7 Suppl 1():S39-44. PubMed ID: 8574734
[TBL] [Abstract][Full Text] [Related]
28. The role of screening for Helicobacter pylori in patients with duodenal ulceration in the primary health care setting.
Rosengren H; Polson RJ
Br J Gen Pract; 1996 Mar; 46(404):177-9. PubMed ID: 8731626
[TBL] [Abstract][Full Text] [Related]
29. Omeprazole, amoxicillin and bismuth for peptic ulcer healing and Helicobacter pylori eradication.
Treiber G; Walker S; Klotz U
Arzneimittelforschung; 1997 Jan; 47(1):47-50. PubMed ID: 9037444
[TBL] [Abstract][Full Text] [Related]
30. Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity.
Bhatia V; Ahuja V; Das B; Bal C; Sharma MP
J Gastroenterol Hepatol; 2004 Jun; 19(6):619-25. PubMed ID: 15151614
[TBL] [Abstract][Full Text] [Related]
31. Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia.
Froehlich F; Gonvers JJ; Wietlisbach V; Burnand B; Hildebrand P; Schneider C; Saraga E; Beglinger C; Vader JP;
Am J Gastroenterol; 2001 Aug; 96(8):2329-36. PubMed ID: 11513170
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population.
Shimoyama T; Fukuda S; Mikami T; Fukushi M; Munakata A
J Gastroenterol; 2004 Oct; 39(10):927-30. PubMed ID: 15549444
[TBL] [Abstract][Full Text] [Related]
33. [Treatment of Helicobacter pylori infection with lansoprazole 30 mg or 60 mg combined with two antibiotics for duodenal ulcers].
Lamouliatte H; Perie F; Joubert-Collin M
Gastroenterol Clin Biol; 2000 May; 24(5):495-500. PubMed ID: 10891736
[TBL] [Abstract][Full Text] [Related]
34. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
Ushiama H; Echizen H; Nachi S; Ohnishi A
Clin Pharmacol Ther; 2002 Jul; 72(1):33-43. PubMed ID: 12152002
[TBL] [Abstract][Full Text] [Related]
35. A retrospective study on efficacy of proton-pump inhibitor-based triple therapy for eradication of Helicobacter pylori in patients with chronic renal failure.
Mak SK; Loo CK; Wong PN; Lo KY; Tong GM; Lam EK; Wong AK
Singapore Med J; 2003 Feb; 44(2):74-8. PubMed ID: 14503780
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori Infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area.
Matsuhisa T; Kawai T; Masaoka T; Suzuki H; Ito M; Kawamura Y; Tokunaga K; Suzuki M; Mine T; Takahashi S; Sakaki N
Helicobacter; 2006 Jun; 11(3):152-8. PubMed ID: 16684262
[TBL] [Abstract][Full Text] [Related]
37. [Effectiveness of the eradication of Helicobacter pylori by treatment with omeprazol, amoxicillin, and clarithromycin according to dosage and administration schedule].
Martín Mir ML; Val J; Fuentes J; García S; Yus C; Simón MA; Gomollón F
Gastroenterol Hepatol; 1998 Nov; 21(9):432-6. PubMed ID: 9882932
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of the efficacy and tolerability of four different therapeutic regimens for the Helicobacter pylori eradication.
Tursi A; Cammarota G; Montalto M; Papa A; Cuoco L; Veneto GM; Cannizzaro O; Fedeli G; Gasbarrini G
Panminerva Med; 1996 Sep; 38(3):145-9. PubMed ID: 9009677
[TBL] [Abstract][Full Text] [Related]
39. [Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy].
Iwasaki A
Nihon Rinsho; 1999 Jan; 57(1):127-33. PubMed ID: 10036949
[TBL] [Abstract][Full Text] [Related]
40. Dual versus triple therapy in eradication of Helicobacter pylori.
Ohlin B; Cederberg A; Kjellin T; Kullman E; Melén K; von Holstein CS; Thoring M
Hepatogastroenterology; 2002; 49(43):172-5. PubMed ID: 11941946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
